No Data
Analysts Offer Insights on Healthcare Companies: Chromadex (CDXC) and Sagimet Biosciences, Inc. Class A (SGMT)
Sagimet Started at Outperform by Oppenheimer, MASH Drug Cited
Sagimet Biosciences Price Target Announced at $30.00/Share by Oppenheimer
Oppenheimer Initiates Coverage On Sagimet Biosciences With Outperform Rating, Announces Price Target of $30
JMP Securities Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Cuts Target Price to $31
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
102339692 : good results why keep dropping
Jaguar8 OP 102339692 : Always remember, shorts are in all stocks. If it doesn’t have volume, shorts will kill it no matter how good the news is.
102339692 Jaguar8 OP :
OooUpup : I agree. No vol no trajectory but how much vol is good enough to launch?
Jaguar8 OP OooUpup : Depends on the float too